The Castrate Resistant Prostate Cancer market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Castrate resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that does not respond to hormone therapy. The market comprises of therapies targeting different mechanisms ... Read more
